Skip to main content
. 2020 Jun 15;20:169. doi: 10.1186/s12890-020-01188-6

Table 2.

Stratified results for different empirical prescribing. Unadjusted analysis

Monotherapy penicillin G/V (n = 335) Combination penicillin G and gentamicin (n = 149) Other antibiotics (n = 167) p-value*
n (%) n (%) n (%)
Age, years
 Mean 72.8 70.8 70.4 0.29
 Gender, female 150 (44.8) 67 (45.0) 86 (51.5) 0.33
Comorbidities
 COPD 94 (28.1) 44 (29.5) 67 (40.1) 0.02
 Heart failure 73 (21.8) 26 (17.5) 41 (24.6) 0.30
 Diabetes mellitus I or II 50 (14.9) 13 (8.7) 22 (13.2) 0.17
Nursing home resident 27 (8.1) 22 (14.8) 21 (12.6) 0.06
Penicillin allergy 8 (2.4) 2 (1.3) 60 (35.9) 0.00
CRB-65 0.11
 0 57 (17.0) 23 (15.4) 30 (18.0)
 1 127 (37.9) 38 (25.5) 60 (35.9)
 2 87 (26.0) 46 (30.9) 46 (27.5)
 3 15 (4.5) 17 (11.4) 11 (6.6)
 4 2 (0.6) 2 (1.3) 2 (1.2)
 Missing data 47 (14.0) 23 (15.4) 18 (10.8)
Antibiotic use pre-hospitalization 64 (19.1) 40 (26.9) 67 (40.1) 0.00
Treatment amended within 3 days 56 (16.7) 25 (16.8) 25 (15.0) 0.87
IV treatment duration, mean (days) 3.4 4.1 4.1 0.01
Total treatment duration, mean (days) 11.4 12.3 11.3 0.04
Clinical outcomes
 30-day readmission 38 (11.6) 19 (13.4) 33 (20.8) 0.02
 Length of stay (mean) 5.1 5.8 5.0 0.20
 30-day mortality 20 (6.0) 11 (7.4) 13 (7.8) 0.70

CRB-65 Confusion, respiration, blood pressure and age ≥ 65y, COPD Chronic obstructive pulmonary disease, IV intravenous

*Categorical data analyzed using Pearson’s χ2-test and continuous data using ANOVA test